Kristen Oelschlager Net Worth

The estimated Net Worth of Kristen M Oelschlager is at least $5.49 million dollars as of 3 September 2024. Ms. Oelschlager owns over 5,832 units of Castle Biosciences stock worth over $4,184,116 and over the last 3 years she sold CSTL stock worth over $1,300,960. In addition, she makes $0 as Senior Vice President - Clinical Operations at Castle Biosciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Oelschlager CSTL stock SEC Form 4 insiders trading

Kristen has made over 10 trades of the Castle Biosciences stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 5,832 units of CSTL stock worth $170,353 on 3 September 2024.

The largest trade she's ever made was exercising 23,881 units of Castle Biosciences stock on 9 December 2023 worth over $741,027. On average, Kristen trades about 6,750 units every 82 days since 2021. As of 3 September 2024 she still owns at least 134,841 units of Castle Biosciences stock.

You can see the complete history of Ms. Oelschlager stock trades at the bottom of the page.

Kristen Oelschlager biography

Kristen Oelschlager serves as Senior Vice President - Clinical Operations of the Company. Ms. Kristen Oelschlager has served as our Senior Vice President, Clinical Operations since January 2018, previously serving as our Vice President, Clinical Operations from 2013 to 2018, and as our Executive Director of Clinical Operations when she joined the company as one of three initial employees. Ms. Oelschlager brought more than 15 years of experience in clinical nursing, clinical operations services, and clinical research to her position. She has successfully overseen the growth and development of Castle’s laboratory and clinical research functions from early start-up to full commercial operations. Prior to joining Castle, Ms. Oelschlager held senior roles in research operations, including the start-up and growth management of a multi-specialty clinical research department as Director of Clinical Research of Arizona Pulmonary Specialists. Ms. Oelschlager has held Speaker’s Bureau appointments for Actelion Pharmaceuticals, Eli Lilly, and Encysive Pharmaceuticals, has co-authored numerous publications and is a co-inventor of several of Castle Biosciences’ technologies. Ms. Oelschlager attended Purdue University, where she completed core nursing requirements concurrent to receiving an Associate of Science, Nursing from the Indiana Vocational Technical College.

What's Kristen Oelschlager's mailing address?

Kristen's mailing address filed with the SEC is C/O CASTLE BIOSCIENCES, INC., 505 S FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD, TX, 77546.

Insiders trading at Castle Biosciences

Over the last 5 years, insiders at Castle Biosciences have traded over $378,509,770 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold et Joseph C. Iii Cook. On average, Castle Biosciences executives and independent directors trade stock every 6 days with the average trade being worth of $632,640. The most recent stock trade was executed by Derek J Maetzold on 9 September 2024, trading 2,586 units of CSTL stock currently worth $76,184.

What does Castle Biosciences do?

Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Complete history of Ms. Oelschlager stock trades at Castle Biosciences

Castle Biosciences executives and stock owners

Castle Biosciences executives and other stock owners filed with the SEC include:

• Derek Maetzold,
  President, Chief Executive Officer, Founder, Director
• Frank Stokes,
  Chief Financial Officer
• Derek J. Maetzold,
  Founder, CEO, Pres & Director
• Frank Stokes,
  Chief Financial Officer
• G. Bradley Cole,
  Independent Director
• Mara Aspinall,
  Independent Director
• Daniel Bradbury,
  Independent Chairman of the Board
• David Kabakoff,
  Independent Director
• Joseph Cook,
  Independent Director
• Miles Harrison,
  Independent Director
• Bernhard Spiess,
  Chief Business Officer
• Noreen Manning,
  Executive Director - Reimbursement
• Michael Maltby,
  Executive Director - Managed Care
• Bob Cook,
  Vice President - Research & Development
• Alice Izzo,
  Vice President - Marketing
• Kristen Oelschlager,
  Senior Vice President - Clinical Operations
• Toby Juvenal,
  Senior Vice President - Sales
• Dr. Robert W. Cook Ph.D.,
  Sr. VP of R&D
• Toby W. Juvenal,
  Chief Commercial Officer
• Camilla Zuckero,
  Exec. Director of Investor Relations & Corp. Communications
• Kristen M. Oelschlager R.N., RN,
  Chief Operating Officer
• Tobin W Juvenal,
  Chief Commercial Officer
• Rodney Cotton,
  Director
• Tiffany Olson,
  Director
• Bonnie H Anderson,
  Director
• Health Quest Partners, L.P....,
  
• Federico A. Monzon,
  Chief Medical Officer
• Venture Partners 2013 Gp, L...,
  
• Kim Caple,
  Director
• Ellen Goldberg,
  Director